Deerfield Management Company, L.p. (series C) - Net Worth and Insider Trading

Deerfield Management Company, L.p. (series C) Net Worth

The estimated net worth of Deerfield Management Company, L.p. (series C) is at least $54 Million dollars as of 2025-07-02. Deerfield Management Company, L.p. (series C) is the of DA32 Life Science Tech Acquisition Corp and owns about 3,850,000 shares of DA32 Life Science Tech Acquisition Corp (DALS) stock worth over $40 Million. Deerfield Management Company, L.p. (series C) is also the of eHealth Inc and owns about 3,264,588 shares of eHealth Inc (EHTH) stock worth over $14 Million. Details can be seen in Deerfield Management Company, L.p. (series C)'s Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Deerfield Management Company, L.p. (series C) has not made any transactions after 2021-07-30 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Deerfield Management Company, L.p. (series C)

Deerfield Management Company, L.p. (series C) Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Deerfield Management Company, L.p. (series C) owns 85 companies in total, including Oncorus Inc (ONCR) , Larimar Therapeutics Inc (LRMR) , and CalciMedica Inc (CALC) among others .

Click here to see the complete history of Deerfield Management Company, L.p. (series C)’s form 4 insider trades.

Insider Ownership Summary of Deerfield Management Company, L.p. (series C)

Ticker	Company	Transaction Date	Type of Owner
ONCR	Oncorus Inc	2020-10-01	director & 10 percent owner & other: *Possible Member of 10% Group
LRMR	Larimar Therapeutics Inc	2016-02-09	10 percent owner & other: Possible Member of 10% Group
CALC	CalciMedica Inc	2020-09-24	10 percent owner & other: Possible Member of 10% Group
		2020-08-05	director & 10 percent owner & other: Director by Deputization
		2020-07-23	10 percent owner & other: Possible Member of 10% Group
		2020-07-21	director & 10 percent owner & other: Director by Deputization
		2020-07-09	10 percent owner & other: Possible Member of 10% Group
		2020-06-11	10 percent owner & other: Possible Member of 10% Group
		2020-03-18	10 percent owner & other: Possible Member of 10% Group
		2020-03-13	director & 10 percent owner & other: Director by Deputization
		2020-02-12	10 percent owner & other: Possible Member of 10% Group
		2020-02-05	10 percent owner & other: Possible Member of 10% Group
		2020-01-29	10 percent owner & other: Possible Member of 10% Group
		2018-03-27	10 percent owner & other: *Director by Deputization
		2019-11-08	director & 10 percent owner & other: * Director by Deputization
		2019-10-24	10 percent owner & other: Possible Member of 10% Group
		2019-10-02	10 percent owner & other: Possible Member of 10% Group
		2019-07-17	10 percent owner & other: Possible Member of 10% Group
		2018-10-22	10 percent owner & other: Possible Member of 10% Group
		2019-03-06	10 percent owner & other: Possible Member of 10% Group
		2019-02-08	10 percent owner & other: Possible Member of 10% Group
		2018-09-26	10 percent owner & other: Possible Member of 10% Group
		2018-07-23	10 percent owner & other: Possible Member of 10% Group
		2018-07-23	10 percent owner & other: Possible member of 10% group
		2018-04-30	10 percent owner & other: *Possible member of 10% group
		2014-10-21	10 percent owner & other: Possible Member of 10% Group
		2018-05-23	10 percent owner & other: *Possible member of 10% group
		2018-05-08	10 percent owner & other: *Possible member of 10% group
		2018-02-15	10 percent owner & other: Possible Member of 10% Group
		2017-10-04	10 percent owner & other: Possible Member of 10% Group
		2016-12-16	10 percent owner & other: Possible Member of 10% Group
		2015-03-06	10 percent owner & other: Possible Member of 10% Group
		2017-01-24	10 percent owner & other: Possible Member of 10% Group
		2016-12-12	10 percent owner & other: Possible Member of 10% Group
		2014-12-23	10 percent owner & other: Possible Member of 10% Group
		2015-06-16	10 percent owner & other: Possible Member of 10% Group
		2016-07-25	10 percent owner & other: Possible Member of 10% Group
		2015-02-10	10 percent owner & other: Possible Member of 10% Group
		2016-06-29	10 percent owner & other: Possible Member of 10% Group
		2016-02-19	10 percent owner & other: Possible Member of 10% Group
		2016-02-10	10 percent owner & other: Possible Member of 10% Group
		2016-02-02	10 percent owner & other: Possible Member of 10% Group
		2015-07-10	10 percent owner & other: Possible Member of 10% Group
		2015-10-07	10 percent owner & other: Possible Member of 10% Group
		2015-10-07	10 percent owner & other: Possible Member of 10% Group
		2015-05-11	10 percent owner & other: Possible Member of 10% Group
		2015-09-16	10 percent owner & other: Possible Member of 10% Group
		2015-07-28	10 percent owner & other: Possible Member of 10% Group
		2015-05-06	10 percent owner & other: Possible Member of 10% Group
		2015-03-25	10 percent owner & other: Possible Member of 10% Group
		2015-02-11	10 percent owner & other: Possible Member of 10% Group
		2014-11-21	10 percent owner & other: Possible Member of 10% Group
		2014-08-06	10 percent owner & other: Possible Members of 10% Group
		2014-08-05	10 percent owner & other: Possible Members of 10% Group
		2014-04-22	10 percent owner & other: Possible Members of 10% Group
		2012-12-04	10 percent owner & other: Possible Member of 10% Group
		2010-11-03	10 percent owner & other: Possible Members of 10% Group
		2011-04-04	10 percent owner & other: Possible Members of 10% Group
		2008-10-27	10 percent owner
		2010-08-16	10 percent owner & other: Possible Members of 10% Group
		2009-07-13	10 percent owner
		2008-03-11	10 percent owner
		2006-01-31	10 percent owner & other: Possible Members of 10% Group
		2007-11-05	10 percent owner & other: Possible Member of 10% Group
		2007-10-19	10 percent owner
		2021-03-25	10 percent owner & other: Possible Member of 10% Group
		2018-02-15	director & 10 percent owner & other: Director by Deputization
		2021-04-29	10 percent owner & other: Possible Member of 10% Group
		2020-03-10	director & 10 percent owner & other: *Director by Deputization
		2020-07-16	director & 10 percent owner & other: *Director by Deputization
		2020-02-04	10 percent owner & other: Possible Member of 10% Group
		2020-02-01	10 percent owner & other: Possible Member of 10% Group
		2022-05-05	10 percent owner & other: *Possible Member of 10% Group
		2021-10-21	10 percent owner & other: *Possible Member of 10% Group
		2021-05-26	10 percent owner & other: *Possible Member of 10% Group
		2021-07-28	director & 10 percent owner & other: Director by Deputization
		2021-07-30	director & 10 percent owner & other: Director by deputization
		2020-02-01	10 percent owner & other: Possible Member of 10% Group
		2018-05-08	10 percent owner & other: *Possible member of 10% group
		2022-11-08	director & 10 percent owner & other: * Director by deputization
		2020-02-01	10 percent owner & other: Possible Member of 10% Group
		2022-11-08	10 percent owner & other: Possible Member of 10% Group
		2022-11-08	director & 10 percent owner & other: * Director by deputization
		2022-11-08	10 percent owner & other: Possible Member of 10% Group
		2019-10-02	10 percent owner & other: Possible Member of 10% Group

Deerfield Management Company, L.p. (series C) Latest Holdings Summary

Deerfield Management Company, L.p. (series C) currently owns a total of 2 stocks. Among these stocks, Deerfield Management Company, L.p. (series C) owns 3,850,000 shares of DA32 Life Science Tech Acquisition Corp (DALS) as of July 30, 2021, with a value of $40 Million and a weighting of 73.67%. Deerfield Management Company, L.p. (series C) also owns 3,264,588 shares of eHealth Inc (EHTH) as of March 6, 2015, with a value of $14 Million and a weighting of 26.33%.

Latest Holdings of Deerfield Management Company, L.p. (series C)

Ticker	Company	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
DALS	DA32 Life Science Tech Acquisition Corp	2021-07-30	3,850,000	10.32	39,732,000
EHTH	eHealth Inc	2015-03-06	3,264,588	4.35	14,200,958

Holding Weightings of Deerfield Management Company, L.p. (series C)

Deerfield Management Company, L.p. (series C) Form 4 Trading Tracker

According to the SEC Form 4 filings, Deerfield Management Company, L.p. (series C) has made a total of 1 transactions in DA32 Life Science Tech Acquisition Corp (DALS) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in DA32 Life Science Tech Acquisition Corp is the acquisition of 1,600,000 shares on July 30, 2021, which cost Deerfield Management Company, L.p. (series C) around $16 Million.

According to the SEC Form 4 filings, Deerfield Management Company, L.p. (series C) has made a total of 0 transactions in eHealth Inc (EHTH) over the past 5 years. The most-recent trade in eHealth Inc is the sale of 1,342,573 shares on March 6, 2015, which brought Deerfield Management Company, L.p. (series C) around $13 Million.

Insider Trading History of Deerfield Management Company, L.p. (series C)

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Deerfield Management Company, L.p. (series C) Trading Performance

GuruFocus tracks the stock performance after each of Deerfield Management Company, L.p. (series C)'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Deerfield Management Company, L.p. (series C) is -2%. GuruFocus also compares Deerfield Management Company, L.p. (series C)'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Deerfield Management Company, L.p. (series C) within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Deerfield Management Company, L.p. (series C)'s insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Deerfield Management Company, L.p. (series C)

Average Return

Average return per transaction

Outperforming Transactions

0 out of 1 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	-2.4
Relative Return to S&P 500(%)	-5.44

Deerfield Management Company, L.p. (series C) Ownership Network

Ownership Network List of Deerfield Management Company, L.p. (series C)

No Data

Ownership Network Relation of Deerfield Management Company, L.p. (series C)

Deerfield Management Company, L.p. (series C) Owned Company Details

What does Oncorus Inc do?

Who are the key executives at Oncorus Inc?

Deerfield Management Company, L.p. (series C) is the director & 10 percent owner & other: *Possible Member of 10% Group of Oncorus Inc. Other key executives at Oncorus Inc include Interim CEO Brian J. Shea , Interim CFO Alexander Nolte , and director & 10 percent owner & other: *Possible Member of 10% Group James E Flynn .

Oncorus Inc (ONCR) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Oncorus Inc (ONCR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Oncorus Inc (ONCR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Oncorus Inc (ONCR)'s detailed insider trading history can be found in Insider Trading Tracker table.

Oncorus Inc Insider Transactions

No Available Data

What does Larimar Therapeutics Inc do?

Who are the key executives at Larimar Therapeutics Inc?

Deerfield Management Company, L.p. (series C) is the 10 percent owner & other: Possible Member of 10% Group of Larimar Therapeutics Inc. Other key executives at Larimar Therapeutics Inc include 10 percent owner & other: Possible Member of 10% Group James E Flynn , Chief Development Officer Gopi Shankar , and Chief Medical Officer Russell Clayton .

Larimar Therapeutics Inc (LRMR) Insider Trades Summary

Over the past 18 months, Deerfield Management Company, L.p. (series C) made no insider transaction in Larimar Therapeutics Inc (LRMR). Other recent insider transactions involving Larimar Therapeutics Inc (LRMR) include a net purchase of 4,290,617 shares made by James E Flynn , a net purchase of 57,208 shares made by Thomas Edward Hamilton , and a net purchase of 2,000 shares made by Frank E Thomas .

In summary, during the past 3 months, insiders sold 0 shares of Larimar Therapeutics Inc (LRMR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Larimar Therapeutics Inc (LRMR) were sold and 4,349,825 shares were bought by its insiders, resulting in a net purchase of 4,349,825 shares.

Larimar Therapeutics Inc (LRMR)'s detailed insider trading history can be found in Insider Trading Tracker table.

Larimar Therapeutics Inc Insider Transactions

No Available Data

What does CalciMedica Inc do?

Who are the key executives at CalciMedica Inc?

Deerfield Management Company, L.p. (series C) is the 10 percent owner & other: Possible Member of 10% Group of CalciMedica Inc. Other key executives at CalciMedica Inc include director & 10 percent owner & Chief Business Officer Eric W Roberts , director & 10 percent owner Fred A Middleton , and director & 10 percent owner & Chief Executive Officer A. Rachel Leheny .

CalciMedica Inc (CALC) Insider Trades Summary

Over the past 18 months, Deerfield Management Company, L.p. (series C) made no insider transaction in CalciMedica Inc (CALC). Other recent insider transactions involving CalciMedica Inc (CALC) include a net purchase of 91,933 shares made by Eric W Roberts , a net purchase of 167,054 shares made by Robert N Wilson , and a net purchase of 791,928 shares made by Fred A Middleton .

In summary, during the past 3 months, insiders sold 0 shares of CalciMedica Inc (CALC) in total and bought 22,600 shares, with a net purchase of 22,600 shares. During the past 18 months, 0 shares of CalciMedica Inc (CALC) were sold and 1,842,043 shares were bought by its insiders, resulting in a net purchase of 1,842,043 shares.

CalciMedica Inc (CALC)'s detailed insider trading history can be found in Insider Trading Tracker table.

CalciMedica Inc Insider Transactions

No Available Data

What does Acutus Medical Inc do?

Who are the key executives at Acutus Medical Inc?

Deerfield Management Company, L.p. (series C) is the director & 10 percent owner & other: Director by Deputization of Acutus Medical Inc. Other key executives at Acutus Medical Inc include Interim CFO Takeo Mukai , SVP & Global Sales Kevin Mathews , and Chief People Officer Charlie Piscitello .

Acutus Medical Inc (AFIB) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Acutus Medical Inc (AFIB) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Acutus Medical Inc (AFIB) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Acutus Medical Inc (AFIB)'s detailed insider trading history can be found in Insider Trading Tracker table.

Acutus Medical Inc Insider Transactions

No Available Data

What does Annexon Inc do?

Who are the key executives at Annexon Inc?

Deerfield Management Company, L.p. (series C) is the 10 percent owner & other: Possible Member of 10% Group of Annexon Inc. Other key executives at Annexon Inc include EVP & Chief Scientific Officer Dean Richard Artis , EVP & Chief Financial Officer Jennifer Lew , and EVP & Chief Innovation Officer Ted Yednock .

Annexon Inc (ANNX) Insider Trades Summary

Over the past 18 months, Deerfield Management Company, L.p. (series C) made no insider transaction in Annexon Inc (ANNX). Other recent insider transactions involving Annexon Inc (ANNX) include a net sale of 42,056 shares made by Ted Yednock , a net purchase of 29,715 shares made by William H. Carson , and a net sale of 14,204 shares made by Jennifer Lew .

In summary, during the past 3 months, insiders sold 0 shares of Annexon Inc (ANNX) in total and bought 4,115 shares, with a net purchase of 4,115 shares. During the past 18 months, 90,226 shares of Annexon Inc (ANNX) were sold and 29,715 shares were bought by its insiders, resulting in a net sale of 60,511 shares.

Annexon Inc (ANNX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Annexon Inc Insider Transactions

No Available Data

What does Deerfield Healthcare Technology Acquisitions Corp do?

Who are the key executives at Deerfield Healthcare Technology Acquisitions Corp?

Deerfield Management Company, L.p. (series C) is the director & 10 percent owner & other: Director by Deputization of Deerfield Healthcare Technology Acquisitions Corp. Other key executives at Deerfield Healthcare Technology Acquisitions Corp include director & 10 percent owner & other: Director by Deputization Deerfield Mgmt L.p. , director & 10 percent owner & other: Director by Deputization Deerfield Partners, L.p. , and director & 10 percent owner & other: Director by Deputization James E Flynn .

Deerfield Healthcare Technology Acquisitions Corp (DFHTU) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Deerfield Healthcare Technology Acquisitions Corp (DFHTU) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Deerfield Healthcare Technology Acquisitions Corp (DFHTU) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Deerfield Healthcare Technology Acquisitions Corp (DFHTU)'s detailed insider trading history can be found in Insider Trading Tracker table.

Deerfield Healthcare Technology Acquisitions Corp Insider Transactions

No Available Data

What does Nkarta Inc do?

Who are the key executives at Nkarta Inc?

Deerfield Management Company, L.p. (series C) is the 10 percent owner & other: Possible Member of 10% Group of Nkarta Inc. Other key executives at Nkarta Inc include director & See Remarks Paul J Hastings , See Remarks Alyssa Levin , and Chief Medical Officer David Shook .

Nkarta Inc (NKTX) Insider Trades Summary

Over the past 18 months, Deerfield Management Company, L.p. (series C) made no insider transaction in Nkarta Inc (NKTX). Other recent insider transactions involving Nkarta Inc (NKTX) include a net sale of 30,635 shares made by Paul J Hastings , a net sale of 18,261 shares made by Alicia J. Hager , and a net sale of 12,646 shares made by David Shook .

In summary, during the past 3 months, insiders sold 1,790 shares of Nkarta Inc (NKTX) in total and bought 0 shares, with a net sale of 1,790 shares. During the past 18 months, 86,727 shares of Nkarta Inc (NKTX) were sold and 5,000,000 shares were bought by its insiders, resulting in a net purchase of 4,913,273 shares.

Nkarta Inc (NKTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Nkarta Inc Insider Transactions

No Available Data

What does Generation Bio Co do?

Who are the key executives at Generation Bio Co?

Deerfield Management Company, L.p. (series C) is the 10 percent owner & other: Possible Member of 10% Group of Generation Bio Co. Other key executives at Generation Bio Co include CHIEF OPERATING OFFICER Antoinette Paone , CHIEF LEGAL OFFICER Yalonda Howze , and CHIEF STRATEGY OFFICER Phillip Samayoa .

Generation Bio Co (GBIO) Insider Trades Summary

Over the past 18 months, Deerfield Management Company, L.p. (series C) made no insider transaction in Generation Bio Co (GBIO). Other recent insider transactions involving Generation Bio Co (GBIO) include a net purchase of 210,791 shares made by Anthony G. Quinn , and a net sale of 6,719 shares made by Antoinette Paone .

In summary, during the past 3 months, insiders sold 0 shares of Generation Bio Co (GBIO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 6,719 shares of Generation Bio Co (GBIO) were sold and 210,791 shares were bought by its insiders, resulting in a net purchase of 204,072 shares.

Generation Bio Co (GBIO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Generation Bio Co Insider Transactions

No Available Data

What does Lumos Pharma Inc do?

Who are the key executives at Lumos Pharma Inc?

Deerfield Management Company, L.p. (series C) is the 10 percent owner & other: Possible Member of 10% Group of Lumos Pharma Inc. Other key executives at Lumos Pharma Inc include Chief Medical Officer David B Karpf , Chief Business Officer Aaron Schuchart , and 10 percent owner & other: Possible Member of 10% Group James E Flynn .

Lumos Pharma Inc (LUMO) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Lumos Pharma Inc (LUMO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Lumos Pharma Inc (LUMO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Lumos Pharma Inc (LUMO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Lumos Pharma Inc Insider Transactions

No Available Data

What does DFP Healthcare Acquisitions Corp do?

Who are the key executives at DFP Healthcare Acquisitions Corp?

Deerfield Management Company, L.p. (series C) is the director & 10 percent owner & other: Director by Deputization of DFP Healthcare Acquisitions Corp. Other key executives at DFP Healthcare Acquisitions Corp include director & 10 percent owner & other: Director by Deputization Deerfield Mgmt L.p. , director & 10 percent owner & other: Director by Deputization Deerfield Partners, L.p. , and director & 10 percent owner & other: Director by Deputization James E Flynn .

DFP Healthcare Acquisitions Corp (DFPHU) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of DFP Healthcare Acquisitions Corp (DFPHU) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of DFP Healthcare Acquisitions Corp (DFPHU) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

DFP Healthcare Acquisitions Corp (DFPHU)'s detailed insider trading history can be found in Insider Trading Tracker table.

DFP Healthcare Acquisitions Corp Insider Transactions

No Available Data

What does Revolution Medicines Inc do?

Who are the key executives at Revolution Medicines Inc?

Deerfield Management Company, L.p. (series C) is the 10 percent owner & other: Possible Member of 10% Group of Revolution Medicines Inc. Other key executives at Revolution Medicines Inc include General Counsel Jeff Cislini , See Remarks Margaret A Horn , and Chief Financial Officer Jack Anders .

Revolution Medicines Inc (RVMD) Insider Trades Summary

Over the past 18 months, Deerfield Management Company, L.p. (series C) made no insider transaction in Revolution Medicines Inc (RVMD). Other recent insider transactions involving Revolution Medicines Inc (RVMD) include a net sale of 39,210 shares made by Jeff Cislini , a net sale of 246,401 shares made by Mark A Goldsmith , and a net sale of 125,720 shares made by Stephen Michael Kelsey .

In summary, during the past 3 months, insiders sold 29,428 shares of Revolution Medicines Inc (RVMD) in total and bought 0 shares, with a net sale of 29,428 shares. During the past 18 months, 561,898 shares of Revolution Medicines Inc (RVMD) were sold and 1,304,347 shares were bought by its insiders, resulting in a net purchase of 742,449 shares.

Revolution Medicines Inc (RVMD)'s detailed insider trading history can be found in Insider Trading Tracker table.

Revolution Medicines Inc Insider Transactions

No Available Data

What does Schrodinger Inc do?

Who are the key executives at Schrodinger Inc?

Deerfield Management Company, L.p. (series C) is the 10 percent owner & other: Possible Member of 10% Group of Schrodinger Inc. Other key executives at Schrodinger Inc include See Remarks Karen Akinsanya , Vice President & Controller Jenny Herman , and EVP & CFO Geoffrey Craig Porges .

Schrodinger Inc (SDGR) Insider Trades Summary

Over the past 18 months, Deerfield Management Company, L.p. (series C) made no insider transaction in Schrodinger Inc (SDGR). Other recent insider transactions involving Schrodinger Inc (SDGR) include a net sale of 2,312 shares made by Jenny Herman , a net sale of 8,806 shares made by Geoffrey Craig Porges , and a net sale of 2,430 shares made by Robert Lorne Abel .

In summary, during the past 3 months, insiders sold 16,723 shares of Schrodinger Inc (SDGR) in total and bought 0 shares, with a net sale of 16,723 shares. During the past 18 months, 35,274 shares of Schrodinger Inc (SDGR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 35,274 shares.

Schrodinger Inc (SDGR)'s detailed insider trading history can be found in Insider Trading Tracker table.

Schrodinger Inc Insider Transactions

No Available Data

What does Black Diamond Therapeutics Inc do?

Who are the key executives at Black Diamond Therapeutics Inc?

Deerfield Management Company, L.p. (series C) is the 10 percent owner & other: Possible Member of 10% Group of Black Diamond Therapeutics Inc. Other key executives at Black Diamond Therapeutics Inc include 10 percent owner Biotech Growth N V , 10 percent owner Versant Venture Capital Vi, L.p. , and director & 10 percent owner Ali Behbahani .

Black Diamond Therapeutics Inc (BDTX) Insider Trades Summary

Over the past 18 months, Deerfield Management Company, L.p. (series C) made no insider transaction in Black Diamond Therapeutics Inc (BDTX). Other recent insider transactions involving Black Diamond Therapeutics Inc (BDTX) include a net sale of 5,784,292 shares made by Biotech Growth N V , and a net sale of 221,600 shares made by Versant Venture Capital Vi, L.p. .

In summary, during the past 3 months, insiders sold 0 shares of Black Diamond Therapeutics Inc (BDTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 6,005,892 shares of Black Diamond Therapeutics Inc (BDTX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 6,005,892 shares.

Black Diamond Therapeutics Inc (BDTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Black Diamond Therapeutics Inc Insider Transactions

No Available Data

What does Homology Medicines Inc do?

Who are the key executives at Homology Medicines Inc?

Deerfield Management Company, L.p. (series C) is the 10 percent owner & other: *Director by Deputization of Homology Medicines Inc. Other key executives at Homology Medicines Inc include director & President & CEO Arthur Tzianabos , See Remarks Paul Alloway , and Chief Scientific Officer Albert Seymour .

Homology Medicines Inc (FIXX) Insider Trades Summary

Over the past 18 months, Deerfield Management Company, L.p. (series C) made no insider transaction in Homology Medicines Inc (FIXX). Other recent insider transactions involving Homology Medicines Inc (FIXX) include a net sale of 13,037 shares made by Arthur Tzianabos , a net sale of 7,280 shares made by Paul Alloway , and a net sale of 1,708 shares made by .

In summary, during the past 3 months, insiders sold 0 shares of Homology Medicines Inc (FIXX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 1,224 shares of Homology Medicines Inc (FIXX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 1,224 shares.

Homology Medicines Inc (FIXX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Homology Medicines Inc Insider Transactions

No Available Data

What does AdaptHealth Corp do?

Who are the key executives at AdaptHealth Corp?

Deerfield Management Company, L.p. (series C) is the director & 10 percent owner & other: * Director by Deputization of AdaptHealth Corp. Other key executives at AdaptHealth Corp include Chief Accounting Officer Frank Mullen , 10 percent owner Oep Vii Project A-i Co-investment Partners, L.p. , and 10 percent owner Oep Vii Project A Co-investment Partners, L.p. .

AdaptHealth Corp (DFBHU) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of AdaptHealth Corp (DFBHU) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of AdaptHealth Corp (DFBHU) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

AdaptHealth Corp (DFBHU)'s detailed insider trading history can be found in Insider Trading Tracker table.

AdaptHealth Corp Insider Transactions

No Available Data

What does Cabaletta Bio Inc do?

Who are the key executives at Cabaletta Bio Inc?

Deerfield Management Company, L.p. (series C) is the 10 percent owner & other: Possible Member of 10% Group of Cabaletta Bio Inc. Other key executives at Cabaletta Bio Inc include EVP & Science & Technology Gwendolyn Binder , director & President & CEO Steven Nichtberger , and Chief Financial Officer Anup Marda .

Cabaletta Bio Inc (CABA) Insider Trades Summary

Over the past 18 months, Deerfield Management Company, L.p. (series C) made no insider transaction in Cabaletta Bio Inc (CABA). Other recent insider transactions involving Cabaletta Bio Inc (CABA) include a net sale of 11,000 shares made by Gwendolyn Binder ,

In summary, during the past 3 months, insiders sold 0 shares of Cabaletta Bio Inc (CABA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 11,000 shares of Cabaletta Bio Inc (CABA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 11,000 shares.

Cabaletta Bio Inc (CABA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Cabaletta Bio Inc Insider Transactions

No Available Data

What does Frequency Therapeutics Inc do?

Who are the key executives at Frequency Therapeutics Inc?

Deerfield Management Company, L.p. (series C) is the 10 percent owner & other: Possible Member of 10% Group of Frequency Therapeutics Inc. Other key executives at Frequency Therapeutics Inc include director & President and CEO David L. Lucchino , VP Finance & Operations Richard J. Mitrano , and Chief Scientific Officer Christopher R. Loose .

Frequency Therapeutics Inc (FREQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Frequency Therapeutics Inc (FREQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Frequency Therapeutics Inc (FREQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Frequency Therapeutics Inc (FREQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Frequency Therapeutics Inc Insider Transactions

No Available Data

What does Mirum Pharmaceuticals Inc do?

Who are the key executives at Mirum Pharmaceuticals Inc?

Deerfield Management Company, L.p. (series C) is the 10 percent owner & other: Possible Member of 10% Group of Mirum Pharmaceuticals Inc. Other key executives at Mirum Pharmaceuticals Inc include SVP & Global Controller Jolanda Howe , Chief Operating Officer Peter Radovich , and director & President and CEO Christopher Peetz .

Mirum Pharmaceuticals Inc (MIRM) Insider Trades Summary

Over the past 18 months, Deerfield Management Company, L.p. (series C) made no insider transaction in Mirum Pharmaceuticals Inc (MIRM). Other recent insider transactions involving Mirum Pharmaceuticals Inc (MIRM) include a net sale of 66,875 shares made by Jolanda Howe , a net sale of 38,032 shares made by Peter Radovich , and a net sale of 101,929 shares made by Christopher Peetz .

In summary, during the past 3 months, insiders sold 11,406 shares of Mirum Pharmaceuticals Inc (MIRM) in total and bought 0 shares, with a net sale of 11,406 shares. During the past 18 months, 265,258 shares of Mirum Pharmaceuticals Inc (MIRM) were sold and 10,709 shares were bought by its insiders, resulting in a net sale of 254,549 shares.

Mirum Pharmaceuticals Inc (MIRM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Mirum Pharmaceuticals Inc Insider Transactions

No Available Data

What does Aclaris Therapeutics Inc do?

Who are the key executives at Aclaris Therapeutics Inc?

Deerfield Management Company, L.p. (series C) is the 10 percent owner & other: Possible Member of 10% Group of Aclaris Therapeutics Inc. Other key executives at Aclaris Therapeutics Inc include Chief Scientific Officer Joseph Monahan , Chief Financial Officer Kevin Balthaser , and Chief Business Officer James Loerop .

Aclaris Therapeutics Inc (ACRS) Insider Trades Summary

Over the past 18 months, Deerfield Management Company, L.p. (series C) made no insider transaction in Aclaris Therapeutics Inc (ACRS). Other recent insider transactions involving Aclaris Therapeutics Inc (ACRS) include a net purchase of 4,854,052 shares made by Braden Michael Leonard , and a net purchase of 666,666 shares made by Anand Mehra .

In summary, during the past 3 months, insiders sold 0 shares of Aclaris Therapeutics Inc (ACRS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Aclaris Therapeutics Inc (ACRS) were sold and 5,520,718 shares were bought by its insiders, resulting in a net purchase of 5,520,718 shares.

Aclaris Therapeutics Inc (ACRS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Aclaris Therapeutics Inc Insider Transactions

No Available Data

What does Shockwave Medical Inc do?

Who are the key executives at Shockwave Medical Inc?

Deerfield Management Company, L.p. (series C) is the 10 percent owner & other: Possible Member of 10% Group of Shockwave Medical Inc. Other key executives at Shockwave Medical Inc include Chief Commercial Officer Isaac Zacharias , VP & Finance Trinh Phung , and director & President & CEO Douglas Evan Godshall .

Shockwave Medical Inc (SWAV) Insider Trades Summary

Over the past 18 months, Deerfield Management Company, L.p. (series C) made no insider transaction in Shockwave Medical Inc (SWAV). Other recent insider transactions involving Shockwave Medical Inc (SWAV) include a net sale of 30,000 shares made by Douglas Evan Godshall , a net sale of 12,000 shares made by Isaac Zacharias , and a net sale of 6,000 shares made by Frank T Watkins .

In summary, during the past 3 months, insiders sold 0 shares of Shockwave Medical Inc (SWAV) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 119,042 shares of Shockwave Medical Inc (SWAV) were sold and 0 shares were bought by its insiders, resulting in a net sale of 119,042 shares.

Shockwave Medical Inc (SWAV)'s detailed insider trading history can be found in Insider Trading Tracker table.

Shockwave Medical Inc Insider Transactions

No Available Data

What does Xeris Biopharma Holdings Inc do?

Who are the key executives at Xeris Biopharma Holdings Inc?

Deerfield Management Company, L.p. (series C) is the 10 percent owner & other: Possible Member of 10% Group of Xeris Biopharma Holdings Inc. Other key executives at Xeris Biopharma Holdings Inc include See Remarks Beth Hecht , Chief Financial Officer Steven Pieper , and See Remarks Shannon John Patrick Jr .

Xeris Biopharma Holdings Inc (XERS) Insider Trades Summary

Over the past 18 months, Deerfield Management Company, L.p. (series C) made no insider transaction in Xeris Biopharma Holdings Inc (XERS). Other recent insider transactions involving Xeris Biopharma Holdings Inc (XERS) include a net purchase of 18,700 shares made by John P. Schmid , a net sale of 40,000 shares made by Beth Hecht , and a net purchase of 25,000 shares made by .

In summary, during the past 3 months, insiders sold 0 shares of Xeris Biopharma Holdings Inc (XERS) in total and bought 25,000 shares, with a net purchase of 25,000 shares. During the past 18 months, 40,000 shares of Xeris Biopharma Holdings Inc (XERS) were sold and 43,700 shares were bought by its insiders, resulting in a net purchase of 3,700 shares.

Xeris Biopharma Holdings Inc (XERS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Xeris Biopharma Holdings Inc Insider Transactions

No Available Data

What does Arvinas Inc do?

Who are the key executives at Arvinas Inc?

Deerfield Management Company, L.p. (series C) is the 10 percent owner & other: Possible Member of 10% Group of Arvinas Inc. Other key executives at Arvinas Inc include Chief Accounting Officer David K Loomis , director & President and CEO John G Houston , and Senior Vice President & Biology Ian Taylor .

Arvinas Inc (ARVN) Insider Trades Summary

Over the past 18 months, Deerfield Management Company, L.p. (series C) made no insider transaction in Arvinas Inc (ARVN). Other recent insider transactions involving Arvinas Inc (ARVN) include a net sale of 36,534 shares made by John G Houston , a net sale of 10,721 shares made by Ian Taylor , and a net sale of 8,658 shares made by .

In summary, during the past 3 months, insiders sold 8,283 shares of Arvinas Inc (ARVN) in total and bought 0 shares, with a net sale of 8,283 shares. During the past 18 months, 73,478 shares of Arvinas Inc (ARVN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 73,478 shares.

Arvinas Inc (ARVN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Arvinas Inc Insider Transactions

No Available Data

What does Aerie Pharmaceuticals Inc do?

Who are the key executives at Aerie Pharmaceuticals Inc?

Deerfield Management Company, L.p. (series C) is the 10 percent owner & other: Possible Member of 10% Group of Aerie Pharmaceuticals Inc. Other key executives at Aerie Pharmaceuticals Inc include Chief Financial Officer Peter Frederick Lang , director & Chief Executive Officer Raj Kannan , and Vice President of Finance Jeffrey Calabrese .

Aerie Pharmaceuticals Inc (AERI) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Aerie Pharmaceuticals Inc (AERI) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Aerie Pharmaceuticals Inc (AERI) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Aerie Pharmaceuticals Inc (AERI)'s detailed insider trading history can be found in Insider Trading Tracker table.

Aerie Pharmaceuticals Inc Insider Transactions

No Available Data

What does Constellation Pharmaceuticals Inc do?

Who are the key executives at Constellation Pharmaceuticals Inc?

Deerfield Management Company, L.p. (series C) is the 10 percent owner & other: Possible member of 10% group of Constellation Pharmaceuticals Inc. Other key executives at Constellation Pharmaceuticals Inc include Chief Financial Officer Emma Reeve , 10 percent owner Column Group L P , and See Remarks Karen Valentine .

Constellation Pharmaceuticals Inc (CNST) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Constellation Pharmaceuticals Inc (CNST) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Constellation Pharmaceuticals Inc (CNST) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Constellation Pharmaceuticals Inc (CNST)'s detailed insider trading history can be found in Insider Trading Tracker table.

Constellation Pharmaceuticals Inc Insider Transactions

No Available Data

What does Avadel Pharmaceuticals PLC do?

Who are the key executives at Avadel Pharmaceuticals PLC?

Deerfield Management Company, L.p. (series C) is the 10 percent owner & other: *Possible member of 10% group of Avadel Pharmaceuticals PLC. Other key executives at Avadel Pharmaceuticals PLC include Chief Financial Officer Thomas S Mchugh , director & Chief Executive Officer Greg J Divis , and Chief Commercial Officer Richard J Kim .

Avadel Pharmaceuticals PLC (AVDL) Insider Trades Summary

Over the past 18 months, Deerfield Management Company, L.p. (series C) made no insider transaction in Avadel Pharmaceuticals PLC (AVDL). Other recent insider transactions involving Avadel Pharmaceuticals PLC (AVDL) include a net purchase of 9,300 shares made by Thomas S Mchugh , a net purchase of 8,000 shares made by Linda Palczuk , and a net purchase of 30,000 shares made by Eric J Ende .

In summary, during the past 3 months, insiders sold 0 shares of Avadel Pharmaceuticals PLC (AVDL) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Avadel Pharmaceuticals PLC (AVDL) were sold and 87,579 shares were bought by its insiders, resulting in a net purchase of 87,579 shares.

Avadel Pharmaceuticals PLC (AVDL)'s detailed insider trading history can be found in Insider Trading Tracker table.

Avadel Pharmaceuticals PLC Insider Transactions

No Available Data

What does Protara Therapeutics Inc do?

Who are the key executives at Protara Therapeutics Inc?

Deerfield Management Company, L.p. (series C) is the 10 percent owner & other: Possible Member of 10% Group of Protara Therapeutics Inc. Other key executives at Protara Therapeutics Inc include Sr. Vice President & Research Jacqueline Zummo , 10 percent owner Opaleye Management Inc. , and Chief Financial Officer Patrick Fabbio .

Protara Therapeutics Inc (TARA) Insider Trades Summary

Over the past 18 months, Deerfield Management Company, L.p. (series C) made no insider transaction in Protara Therapeutics Inc (TARA). Other recent insider transactions involving Protara Therapeutics Inc (TARA) include a net sale of 703,460 shares made by Opaleye Management Inc. , a net purchase of 40,000 shares made by Richard S Levy , and a net sale of 21,224 shares made by Jacqueline Zummo .

In summary, during the past 3 months, insiders sold 0 shares of Protara Therapeutics Inc (TARA) in total and bought 40,000 shares, with a net purchase of 40,000 shares. During the past 18 months, 724,684 shares of Protara Therapeutics Inc (TARA) were sold and 40,000 shares were bought by its insiders, resulting in a net sale of 684,684 shares.

Protara Therapeutics Inc (TARA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Protara Therapeutics Inc Insider Transactions

No Available Data

What does Kiniksa Pharmaceuticals International PLC do?

Who are the key executives at Kiniksa Pharmaceuticals International PLC?

Deerfield Management Company, L.p. (series C) is the 10 percent owner & other: *Possible member of 10% group of Kiniksa Pharmaceuticals International PLC. Other key executives at Kiniksa Pharmaceuticals International PLC include Chief Business Officer Eben Tessari , Interim CFO Mark Ragosa , and Group VP & Rilonacept GM Ross Moat .

Kiniksa Pharmaceuticals International PLC (KNSA) Insider Trades Summary

Over the past 18 months, Deerfield Management Company, L.p. (series C) made no insider transaction in Kiniksa Pharmaceuticals International PLC (KNSA). Other recent insider transactions involving Kiniksa Pharmaceuticals International PLC (KNSA) include a net sale of 244,593 shares made by Eben Tessari , a net sale of 408,607 shares made by Sanj K Patel , and a net sale of 246,546 shares made by Mark Ragosa .

In summary, during the past 3 months, insiders sold 522,197 shares of Kiniksa Pharmaceuticals International PLC (KNSA) in total and bought 0 shares, with a net sale of 522,197 shares. During the past 18 months, 1,297,332 shares of Kiniksa Pharmaceuticals International PLC (KNSA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 1,297,332 shares.

Kiniksa Pharmaceuticals International PLC (KNSA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Kiniksa Pharmaceuticals International PLC Insider Transactions

No Available Data

What does Mallinckrodt PLC do?

Who are the key executives at Mallinckrodt PLC?

Deerfield Management Company, L.p. (series C) is the 10 percent owner & other: *Possible member of 10% group of Mallinckrodt PLC. Other key executives at Mallinckrodt PLC include director & President and CEO Sigurdur O Olafsson , EVP & Chief Sci. Ofcr Steven J. Romano , and 10 percent owner Fyi S.a R.l. .

Mallinckrodt PLC (MNKKQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Mallinckrodt PLC (MNKKQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Mallinckrodt PLC (MNKKQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Mallinckrodt PLC (MNKKQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Mallinckrodt PLC Insider Transactions

No Available Data

What does Catalyst Biosciences Inc do?

Who are the key executives at Catalyst Biosciences Inc?

Deerfield Management Company, L.p. (series C) is the 10 percent owner & other: Possible Member of 10% Group of Catalyst Biosciences Inc. Other key executives at Catalyst Biosciences Inc include director & Chief Executive Officer Charles C Wu , director & President Songjiang Ma , and Chief Operating Officer Weiguo Ye .

Catalyst Biosciences Inc (CBIO) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Catalyst Biosciences Inc (CBIO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Catalyst Biosciences Inc (CBIO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Catalyst Biosciences Inc (CBIO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Catalyst Biosciences Inc Insider Transactions

No Available Data

What does Rhythm Pharmaceuticals Inc do?

Who are the key executives at Rhythm Pharmaceuticals Inc?

Deerfield Management Company, L.p. (series C) is the 10 percent owner & other: Possible Member of 10% Group of Rhythm Pharmaceuticals Inc. Other key executives at Rhythm Pharmaceuticals Inc include Corporate Controller & CAO Christopher Paul German , Chief Human Resources Officer Pamela J. Cramer , and CFO and Treasurer Hunter C Smith .

Rhythm Pharmaceuticals Inc (RYTM) Insider Trades Summary

Over the past 18 months, Deerfield Management Company, L.p. (series C) made no insider transaction in Rhythm Pharmaceuticals Inc (RYTM). Other recent insider transactions involving Rhythm Pharmaceuticals Inc (RYTM) include a net sale of 121,639 shares made by Pamela J. Cramer , a net sale of 147,884 shares made by Joseph Shulman , and a net sale of 118,525 shares made by Jennifer Chien .

In summary, during the past 3 months, insiders sold 193,837 shares of Rhythm Pharmaceuticals Inc (RYTM) in total and bought 0 shares, with a net sale of 193,837 shares. During the past 18 months, 849,479 shares of Rhythm Pharmaceuticals Inc (RYTM) were sold and 0 shares were bought by its insiders, resulting in a net sale of 849,479 shares.

Rhythm Pharmaceuticals Inc (RYTM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Rhythm Pharmaceuticals Inc Insider Transactions

No Available Data

What does Societal CDMO Inc do?

Who are the key executives at Societal CDMO Inc?

Deerfield Management Company, L.p. (series C) is the 10 percent owner & other: Possible Member of 10% Group of Societal CDMO Inc. Other key executives at Societal CDMO Inc include director & Chief Executive Officer Enloe J David Jr , director & 10 percent owner Mathew Paul Arens , and 10 percent owner Awm Investment Company, Inc. .

Societal CDMO Inc (SCTL) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Societal CDMO Inc (SCTL) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Societal CDMO Inc (SCTL) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Societal CDMO Inc (SCTL)'s detailed insider trading history can be found in Insider Trading Tracker table.

Societal CDMO Inc Insider Transactions

No Available Data

What does eHealth Inc do?

Who are the key executives at eHealth Inc?

Deerfield Management Company, L.p. (series C) is the 10 percent owner & other: Possible Member of 10% Group of eHealth Inc. Other key executives at eHealth Inc include SVP & General Counsel & Secr. Gavin G. Galimi , SVP & Chief Financial Officer John J Stelben , and director & Chief Executive Officer Soistman Francis S Jr .

eHealth Inc (EHTH) Insider Trades Summary

Over the past 18 months, Deerfield Management Company, L.p. (series C) made no insider transaction in eHealth Inc (EHTH). Other recent insider transactions involving eHealth Inc (EHTH) include a net purchase of 26,865 shares made by Gavin G. Galimi , a net purchase of 50,000 shares made by Soistman Francis S Jr , and a net purchase of 20,000 shares made by John J Stelben .

In summary, during the past 3 months, insiders sold 0 shares of eHealth Inc (EHTH) in total and bought 9,500 shares, with a net purchase of 9,500 shares. During the past 18 months, 20,000 shares of eHealth Inc (EHTH) were sold and 96,865 shares were bought by its insiders, resulting in a net purchase of 76,865 shares.

eHealth Inc (EHTH)'s detailed insider trading history can be found in Insider Trading Tracker table.

eHealth Inc Insider Transactions

No Available Data

What does CAS Medical Systems Inc do?

Who are the key executives at CAS Medical Systems Inc?

Deerfield Management Company, L.p. (series C) is the 10 percent owner & other: Possible Member of 10% Group of CAS Medical Systems Inc. Other key executives at CAS Medical Systems Inc include director & President and CEO Thomas M Patton , director & 10 percent owner James E Thomas , and 10 percent owner Thomas, Mcnerney & Partners Ii L.p. .

CAS Medical Systems Inc (CASM) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of CAS Medical Systems Inc (CASM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of CAS Medical Systems Inc (CASM) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

CAS Medical Systems Inc (CASM)'s detailed insider trading history can be found in Insider Trading Tracker table.

CAS Medical Systems Inc Insider Transactions

No Available Data

What does Invuity Inc do?

Who are the key executives at Invuity Inc?

Deerfield Management Company, L.p. (series C) is the 10 percent owner & other: Possible Member of 10% Group of Invuity Inc. Other key executives at Invuity Inc include Chief Financial Officer James H Mackaness , 10 percent owner & other: Possible Member of 10% Group James E Flynn , and 10 percent owner & other: Possible Member of 10% Group Deerfield Mgmt L.p. .

Invuity Inc (IVTY) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Invuity Inc (IVTY) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Invuity Inc (IVTY) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Invuity Inc (IVTY)'s detailed insider trading history can be found in Insider Trading Tracker table.

Invuity Inc Insider Transactions

No Available Data

What does Vanda Pharmaceuticals Inc do?

Who are the key executives at Vanda Pharmaceuticals Inc?

Deerfield Management Company, L.p. (series C) is the 10 percent owner & other: Possible Member of 10% Group of Vanda Pharmaceuticals Inc. Other key executives at Vanda Pharmaceuticals Inc include director & Chief Executive Officer Mihael Hristos Polymeropoulos , VP & Acting CFO & Treasurer Kevin Patrick Moran , and SVP & General Counsel Timothy Williams .

Vanda Pharmaceuticals Inc (VNDA) Insider Trades Summary

Over the past 18 months, Deerfield Management Company, L.p. (series C) made no insider transaction in Vanda Pharmaceuticals Inc (VNDA). Other recent insider transactions involving Vanda Pharmaceuticals Inc (VNDA) include a net purchase of 34,828 shares made by Mihael Hristos Polymeropoulos , a net sale of 14,951 shares made by Kevin Patrick Moran , and a net sale of 12,000 shares made by Stephen Ray Mitchell .

In summary, during the past 3 months, insiders sold 7,000 shares of Vanda Pharmaceuticals Inc (VNDA) in total and bought 30,000 shares, with a net purchase of 23,000 shares. During the past 18 months, 135,349 shares of Vanda Pharmaceuticals Inc (VNDA) were sold and 92,000 shares were bought by its insiders, resulting in a net sale of 43,349 shares.

Vanda Pharmaceuticals Inc (VNDA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Vanda Pharmaceuticals Inc Insider Transactions

No Available Data

What does Alpine Immune Sciences Inc do?

Who are the key executives at Alpine Immune Sciences Inc?

Deerfield Management Company, L.p. (series C) is the 10 percent owner & other: Possible Member of 10% Group of Alpine Immune Sciences Inc. Other key executives at Alpine Immune Sciences Inc include Senior VP and CFO James Paul Rickey , director & Executive Chairman and CEO Mitchell Gold , and director & 10 percent owner Xiangmin Cui .

Alpine Immune Sciences Inc (ALPN) Insider Trades Summary

Over the past 18 months, Deerfield Management Company, L.p. (series C) made no insider transaction in Alpine Immune Sciences Inc (ALPN). Other recent insider transactions involving Alpine Immune Sciences Inc (ALPN) include a net sale of 118,000 shares made by James Paul Rickey , and a net sale of 19 shares made by James N Topper .

In summary, during the past 3 months, insiders sold 0 shares of Alpine Immune Sciences Inc (ALPN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 118,019 shares of Alpine Immune Sciences Inc (ALPN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 118,019 shares.

Alpine Immune Sciences Inc (ALPN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Alpine Immune Sciences Inc Insider Transactions

No Available Data

What does Audentes Therapeutics Inc do?

Who are the key executives at Audentes Therapeutics Inc?

Deerfield Management Company, L.p. (series C) is the 10 percent owner & other: Possible Member of 10% Group of Audentes Therapeutics Inc. Other key executives at Audentes Therapeutics Inc include President and COO Natalie C. Holles , SVP & Chief Medical Officer Edward R. Conner , and Executive Vice President & CFO Thomas P Soloway .

Audentes Therapeutics Inc (BOLD) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Audentes Therapeutics Inc (BOLD) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Audentes Therapeutics Inc (BOLD) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Audentes Therapeutics Inc (BOLD)'s detailed insider trading history can be found in Insider Trading Tracker table.

Audentes Therapeutics Inc Insider Transactions

No Available Data

What does Axogen Inc do?

Who are the key executives at Axogen Inc?

Deerfield Management Company, L.p. (series C) is the 10 percent owner & other: Possible Member of 10% Group of Axogen Inc. Other key executives at Axogen Inc include VP & Clinical&Translational Sc Erick Wayne Devinney , Chief R&D Officer Angelo Scopelianos , and director & CEO Karen L. Zaderej .

Axogen Inc (AXGN) Insider Trades Summary

Over the past 18 months, Deerfield Management Company, L.p. (series C) made no insider transaction in Axogen Inc (AXGN). Other recent insider transactions involving Axogen Inc (AXGN) include a net sale of 49,518 shares made by Joseph A. Tyndall , a net sale of 42,343 shares made by Michael Patrick Donovan , and a net sale of 19,689 shares made by Erick Wayne Devinney .

In summary, during the past 3 months, insiders sold 73,956 shares of Axogen Inc (AXGN) in total and bought 0 shares, with a net sale of 73,956 shares. During the past 18 months, 212,149 shares of Axogen Inc (AXGN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 212,149 shares.

Axogen Inc (AXGN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Axogen Inc Insider Transactions

No Available Data

What does Syros Pharmaceuticals Inc do?

Who are the key executives at Syros Pharmaceuticals Inc?

Deerfield Management Company, L.p. (series C) is the 10 percent owner & other: Possible Member of 10% Group of Syros Pharmaceuticals Inc. Other key executives at Syros Pharmaceuticals Inc include director & 10 percent owner & President & CEO Nancy A Simonian , Chief Legal Officer Gerald E Quirk , and Chief Development Officer Kristin Stephens .

Syros Pharmaceuticals Inc (SYRS) Insider Trades Summary

Over the past 18 months, Deerfield Management Company, L.p. (series C) made no insider transaction in Syros Pharmaceuticals Inc (SYRS). Other recent insider transactions involving Syros Pharmaceuticals Inc (SYRS) include a net sale of 22,700 shares made by David Roth , a net sale of 171,783 shares made by Nancy A Simonian , and a net sale of 37,803 shares made by Jason Haas .

In summary, during the past 3 months, insiders sold 0 shares of Syros Pharmaceuticals Inc (SYRS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 549,873 shares of Syros Pharmaceuticals Inc (SYRS) were sold and 200,000 shares were bought by its insiders, resulting in a net sale of 349,873 shares.

Syros Pharmaceuticals Inc (SYRS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Syros Pharmaceuticals Inc Insider Transactions

No Available Data

What does XenoPort Inc do?

Who are the key executives at XenoPort Inc?

Deerfield Management Company, L.p. (series C) is the 10 percent owner & other: Possible Member of 10% Group of XenoPort Inc. Other key executives at XenoPort Inc include See Remarks William G Harris , 10 percent owner & other: Possible Member of 10% Group Deerfield Mgmt L.p. , and 10 percent owner & other: Possible Member of 10% Group Deerfield Partners, L.p. .

XenoPort Inc (XNPT) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of XenoPort Inc (XNPT) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of XenoPort Inc (XNPT) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

XenoPort Inc (XNPT)'s detailed insider trading history can be found in Insider Trading Tracker table.

XenoPort Inc Insider Transactions

No Available Data

What does AveXis Inc do?

Who are the key executives at AveXis Inc?

Deerfield Management Company, L.p. (series C) is the 10 percent owner & other: Possible Member of 10% Group of AveXis Inc. Other key executives at AveXis Inc include director & President & CEO Sean P. Nolan , 10 percent owner Ag Novartis , and Chief Financial Officer Phillip B. Donenberg .

AveXis Inc (AVXS) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of AveXis Inc (AVXS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of AveXis Inc (AVXS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

AveXis Inc (AVXS)'s detailed insider trading history can be found in Insider Trading Tracker table.

AveXis Inc Insider Transactions

No Available Data

What does Editas Medicine Inc do?

Who are the key executives at Editas Medicine Inc?

Deerfield Management Company, L.p. (series C) is the 10 percent owner & other: Possible Member of 10% Group of Editas Medicine Inc. Other key executives at Editas Medicine Inc include EVP & CHIEF SCIENTIFIC OFFICER Linda Burkly , director & CEO Gilmore Neil O'neill , and EVP & CHIEF FINANCIAL OFFICER Erick Lucera .

Editas Medicine Inc (EDIT) Insider Trades Summary

Over the past 18 months, Deerfield Management Company, L.p. (series C) made no insider transaction in Editas Medicine Inc (EDIT). Other recent insider transactions involving Editas Medicine Inc (EDIT) include a net sale of 125,012 shares made by Gilmore Neil O'neill , a net sale of 28,516 shares made by Baisong Mei , and a net sale of 15,503 shares made by Linda Burkly .

In summary, during the past 3 months, insiders sold 16,364 shares of Editas Medicine Inc (EDIT) in total and bought 0 shares, with a net sale of 16,364 shares. During the past 18 months, 195,923 shares of Editas Medicine Inc (EDIT) were sold and 45,000 shares were bought by its insiders, resulting in a net sale of 150,923 shares.

Editas Medicine Inc (EDIT)'s detailed insider trading history can be found in Insider Trading Tracker table.

Editas Medicine Inc Insider Transactions

No Available Data

What does Streamline Health Solutions Inc do?

Who are the key executives at Streamline Health Solutions Inc?

Deerfield Management Company, L.p. (series C) is the 10 percent owner & other: Possible Member of 10% Group of Streamline Health Solutions Inc. Other key executives at Streamline Health Solutions Inc include President Benjamin Louis Stilwill , Interim CFO Reeves Bryant J Iii , and Chief People Officer Wendy L Lucio .

Streamline Health Solutions Inc (STRM) Insider Trades Summary

Over the past 18 months, Deerfield Management Company, L.p. (series C) made no insider transaction in Streamline Health Solutions Inc (STRM). Other recent insider transactions involving Streamline Health Solutions Inc (STRM) include a net purchase of 6,300 shares made by Benjamin Louis Stilwill ,

In summary, during the past 3 months, insiders sold 0 shares of Streamline Health Solutions Inc (STRM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Streamline Health Solutions Inc (STRM) were sold and 420 shares were bought by its insiders, resulting in a net purchase of 420 shares.

Streamline Health Solutions Inc (STRM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Streamline Health Solutions Inc Insider Transactions

No Available Data

What does Alimera Sciences Inc do?

Who are the key executives at Alimera Sciences Inc?

Deerfield Management Company, L.p. (series C) is the 10 percent owner & other: Possible Member of 10% Group of Alimera Sciences Inc. Other key executives at Alimera Sciences Inc include 10 percent owner Caligan Partners Lp , other: Chairman Emeritus C. Daniel Myers , and 10 percent owner David Edward Johnson .

Alimera Sciences Inc (ALIM) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Alimera Sciences Inc (ALIM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Alimera Sciences Inc (ALIM) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Alimera Sciences Inc (ALIM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Alimera Sciences Inc Insider Transactions

No Available Data

What does CytomX Therapeutics Inc do?

Who are the key executives at CytomX Therapeutics Inc?

Deerfield Management Company, L.p. (series C) is the 10 percent owner & other: Possible Member of 10% Group of CytomX Therapeutics Inc. Other key executives at CytomX Therapeutics Inc include SVP & Chief Scientific Officer Marcia Belvin , SVP & Finance and Accounting Christopher Ogden , and director & President and CEO Sean A. Mccarthy .

CytomX Therapeutics Inc (CTMX) Insider Trades Summary

Over the past 18 months, Deerfield Management Company, L.p. (series C) made no insider transaction in CytomX Therapeutics Inc (CTMX). Other recent insider transactions involving CytomX Therapeutics Inc (CTMX) include a net sale of 127,288 shares made by Sean A. Mccarthy , a net sale of 50,372 shares made by Marcia Belvin , and a net sale of 25,761 shares made by Christopher Ogden .

In summary, during the past 3 months, insiders sold 81,650 shares of CytomX Therapeutics Inc (CTMX) in total and bought 0 shares, with a net sale of 81,650 shares. During the past 18 months, 237,841 shares of CytomX Therapeutics Inc (CTMX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 237,841 shares.

CytomX Therapeutics Inc (CTMX)'s detailed insider trading history can be found in Insider Trading Tracker table.

CytomX Therapeutics Inc Insider Transactions

No Available Data

What does Antares Pharma Inc do?

Who are the key executives at Antares Pharma Inc?

Deerfield Management Company, L.p. (series C) is the 10 percent owner & other: Possible Member of 10% Group of Antares Pharma Inc. Other key executives at Antares Pharma Inc include See Remarks Peter C Richardson , Executive Vice President & CFO Fred M Powell , and See Remarks Peter J Graham .

Antares Pharma Inc (ATRS) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Antares Pharma Inc (ATRS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Antares Pharma Inc (ATRS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Antares Pharma Inc (ATRS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Antares Pharma Inc Insider Transactions

No Available Data

What does Regenxbio Inc do?

Who are the key executives at Regenxbio Inc?

Deerfield Management Company, L.p. (series C) is the 10 percent owner & other: Possible Member of 10% Group of Regenxbio Inc. Other key executives at Regenxbio Inc include director & See Remarks Kenneth T. Mills , SVP of Technical Operations Curran Simpson , and Chief Medical Officer Steve Pakola .

Regenxbio Inc (RGNX) Insider Trades Summary

Over the past 18 months, Deerfield Management Company, L.p. (series C) made no insider transaction in Regenxbio Inc (RGNX). Other recent insider transactions involving Regenxbio Inc (RGNX) include a net sale of 155,602 shares made by Kenneth T. Mills , a net sale of 51,100 shares made by Argeris N Karabelas , and a net sale of 9,748 shares made by Curran Simpson .

In summary, during the past 3 months, insiders sold 20,602 shares of Regenxbio Inc (RGNX) in total and bought 0 shares, with a net sale of 20,602 shares. During the past 18 months, 229,328 shares of Regenxbio Inc (RGNX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 229,328 shares.

Regenxbio Inc (RGNX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Regenxbio Inc Insider Transactions

No Available Data

What does Neos Therapeutics Inc do?

Who are the key executives at Neos Therapeutics Inc?

Deerfield Management Company, L.p. (series C) is the 10 percent owner & other: Possible Member of 10% Group of Neos Therapeutics Inc. Other key executives at Neos Therapeutics Inc include director & Chief Executive Officer Gerald W. Mclaughlin , Chief Financial Officer Richard I Eisenstadt , and SVP & General Counsel John M Limongelli .

Neos Therapeutics Inc (NEOS) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Neos Therapeutics Inc (NEOS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Neos Therapeutics Inc (NEOS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Neos Therapeutics Inc (NEOS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Neos Therapeutics Inc Insider Transactions

No Available Data

What does aTyr Pharma Inc do?

Who are the key executives at aTyr Pharma Inc?

Deerfield Management Company, L.p. (series C) is the 10 percent owner & other: Possible Member of 10% Group of aTyr Pharma Inc. Other key executives at aTyr Pharma Inc include Chief Financial Officer Jill Marie Broadfoot , See Remarks Nancy Krueger , and Chief Medical Officer Sanjay Shukla .

aTyr Pharma Inc (ATYR) Insider Trades Summary

Over the past 18 months, Deerfield Management Company, L.p. (series C) made no insider transaction in aTyr Pharma Inc (ATYR). Other recent insider transactions involving aTyr Pharma Inc (ATYR) include a net purchase of 2,156 shares made by Jill Marie Broadfoot , a net purchase of 4,101 shares made by Nancy Krueger , and a net purchase of 100,000 shares made by Paul Schimmel .

In summary, during the past 3 months, insiders sold 0 shares of aTyr Pharma Inc (ATYR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 3,743 shares of aTyr Pharma Inc (ATYR) were sold and 183,750 shares were bought by its insiders, resulting in a net purchase of 180,007 shares.

aTyr Pharma Inc (ATYR)'s detailed insider trading history can be found in Insider Trading Tracker table.

aTyr Pharma Inc Insider Transactions

No Available Data

What does SteadyMed Ltd do?

Who are the key executives at SteadyMed Ltd?

Deerfield Management Company, L.p. (series C) is the 10 percent owner & other: Possible Member of 10% Group of SteadyMed Ltd. Other key executives at SteadyMed Ltd include 10 percent owner Orbimed Advisors Llc , 10 percent owner Orbimed Capital Gp Vi Llc , and director & 10 percent owner Brian Jay Stark .

SteadyMed Ltd (STDY) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of SteadyMed Ltd (STDY) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of SteadyMed Ltd (STDY) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

SteadyMed Ltd (STDY)'s detailed insider trading history can be found in Insider Trading Tracker table.

SteadyMed Ltd Insider Transactions

No Available Data

What does Invitae Corp do?

Who are the key executives at Invitae Corp?

Deerfield Management Company, L.p. (series C) is the 10 percent owner & other: Possible Member of 10% Group of Invitae Corp. Other key executives at Invitae Corp include Chief Financial Officer Ana J. Schrank , Chief Commercial Officer Robert M. Guigley , and See Remarks Robert Iv Dickey .

Invitae Corp (NVTAQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Invitae Corp (NVTAQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Invitae Corp (NVTAQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Invitae Corp (NVTAQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Invitae Corp Insider Transactions

No Available Data

What does Dicerna Pharmaceuticals Inc do?

Who are the key executives at Dicerna Pharmaceuticals Inc?

Deerfield Management Company, L.p. (series C) is the 10 percent owner & other: Possible Member of 10% Group of Dicerna Pharmaceuticals Inc. Other key executives at Dicerna Pharmaceuticals Inc include See Remarks Bob D Brown , EVP & Chief Medical Officer Shreeram Aradhye , and director & President and CEO Douglas Fambrough .

Dicerna Pharmaceuticals Inc (DRNA) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Dicerna Pharmaceuticals Inc (DRNA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Dicerna Pharmaceuticals Inc (DRNA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Dicerna Pharmaceuticals Inc (DRNA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Dicerna Pharmaceuticals Inc Insider Transactions

No Available Data

What does Loxo Oncology Inc do?

Who are the key executives at Loxo Oncology Inc?

Deerfield Management Company, L.p. (series C) is the 10 percent owner & other: Possible Members of 10% Group of Loxo Oncology Inc. Other key executives at Loxo Oncology Inc include Senior VP of Finance Jennifer Burstein , director & President & CEO Joshua H. Bilenker , and director & 10 percent owner Steve Elms .

Loxo Oncology Inc (LOXO) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Loxo Oncology Inc (LOXO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Loxo Oncology Inc (LOXO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Loxo Oncology Inc (LOXO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Loxo Oncology Inc Insider Transactions

No Available Data

What does Adverum Biotechnologies Inc do?

Who are the key executives at Adverum Biotechnologies Inc?

Deerfield Management Company, L.p. (series C) is the 10 percent owner & other: Possible Members of 10% Group of Adverum Biotechnologies Inc. Other key executives at Adverum Biotechnologies Inc include Chief Development Officer Setareh Seyedkazemi , director & CEO and Director Laurent Fischer , and Chief Legal Officer Peter Soparkar .

Adverum Biotechnologies Inc (ADVM) Insider Trades Summary

Over the past 18 months, Deerfield Management Company, L.p. (series C) made no insider transaction in Adverum Biotechnologies Inc (ADVM). Other recent insider transactions involving Adverum Biotechnologies Inc (ADVM) include a net purchase of 1,235,943 shares made by Braden Michael Leonard , a net purchase of 130,000 shares made by Lupher, Jr. Mark L. , and a net purchase of 100,000 shares made by James Paul Scopa .

In summary, during the past 3 months, insiders sold 13,010 shares of Adverum Biotechnologies Inc (ADVM) in total and bought 350,000 shares, with a net purchase of 336,990 shares. During the past 18 months, 13,010 shares of Adverum Biotechnologies Inc (ADVM) were sold and 1,258,943 shares were bought by its insiders, resulting in a net purchase of 1,245,933 shares.

Adverum Biotechnologies Inc (ADVM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Adverum Biotechnologies Inc Insider Transactions

No Available Data

What does TriVascular Technologies Inc do?

Who are the key executives at TriVascular Technologies Inc?

Deerfield Management Company, L.p. (series C) is the 10 percent owner & other: Possible Members of 10% Group of TriVascular Technologies Inc. Other key executives at TriVascular Technologies Inc include 10 percent owner Krishna Kittu Kolluri , VP & Gen. Counsel and Secretary Kimberley A. Elting , and Chief Technology Officer Michael V. Chobotov .

TriVascular Technologies Inc (TRIV) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of TriVascular Technologies Inc (TRIV) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of TriVascular Technologies Inc (TRIV) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

TriVascular Technologies Inc (TRIV)'s detailed insider trading history can be found in Insider Trading Tracker table.

TriVascular Technologies Inc Insider Transactions

No Available Data

What does NxStage Medical Inc do?

Who are the key executives at NxStage Medical Inc?

Deerfield Management Company, L.p. (series C) is the 10 percent owner & other: Possible Member of 10% Group of NxStage Medical Inc. Other key executives at NxStage Medical Inc include director & Chief Executive Officer Jeffrey H Burbank , Chief Accounting Officer Kevin Hershberger , and 10 percent owner & other: Possible Member of 10% Group Deerfield Mgmt L.p. .

NxStage Medical Inc (NXTM) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of NxStage Medical Inc (NXTM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of NxStage Medical Inc (NXTM) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

NxStage Medical Inc (NXTM)'s detailed insider trading history can be found in Insider Trading Tracker table.

NxStage Medical Inc Insider Transactions

No Available Data

What does Rigel Pharmaceuticals Inc do?

Who are the key executives at Rigel Pharmaceuticals Inc?

Deerfield Management Company, L.p. (series C) is the 10 percent owner & other: Possible Members of 10% Group of Rigel Pharmaceuticals Inc. Other key executives at Rigel Pharmaceuticals Inc include EVP & Chief Financial Officer Dean L Schorno , Sr VP of Bus Dev and Com Ops Raul R Rodriguez , and EVP & GC & Corp Sec Raymond J. Furey .

Rigel Pharmaceuticals Inc (RIGL) Insider Trades Summary

Over the past 18 months, Deerfield Management Company, L.p. (series C) made no insider transaction in Rigel Pharmaceuticals Inc (RIGL). Other recent insider transactions involving Rigel Pharmaceuticals Inc (RIGL) include a net sale of 62,246 shares made by Raul R Rodriguez , a net sale of 18,440 shares made by David A Santos , and a net sale of 16,398 shares made by Dean L Schorno .

In summary, during the past 3 months, insiders sold 0 shares of Rigel Pharmaceuticals Inc (RIGL) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 27,834 shares of Rigel Pharmaceuticals Inc (RIGL) were sold and 0 shares were bought by its insiders, resulting in a net sale of 27,834 shares.

Rigel Pharmaceuticals Inc (RIGL)'s detailed insider trading history can be found in Insider Trading Tracker table.

Rigel Pharmaceuticals Inc Insider Transactions

No Available Data

What does The Medicines Co do?

Who are the key executives at The Medicines Co?

Deerfield Management Company, L.p. (series C) is the 10 percent owner & other: Possible Members of 10% Group of The Medicines Co. Other key executives at The Medicines Co include Chief Development Officer Peter Wijngaard , EVP & Chief Corp. Dev. Officer Christopher T Cox , and director & Executive Chairman Fredric N Eshelman .

The Medicines Co (MDCO) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of The Medicines Co (MDCO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of The Medicines Co (MDCO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

The Medicines Co (MDCO)'s detailed insider trading history can be found in Insider Trading Tracker table.

The Medicines Co Insider Transactions

No Available Data

What does NeuroMetrix Inc do?

Who are the key executives at NeuroMetrix Inc?

Deerfield Management Company, L.p. (series C) is the 10 percent owner of NeuroMetrix Inc. Other key executives at NeuroMetrix Inc include Chief Financial Officer Thomas T Higgins , other: See Explanation in Footnotes Topline Capital Management, Llc , and 10 percent owner Topline Capital Partners, Lp .

NeuroMetrix Inc (NURO) Insider Trades Summary

Over the past 18 months, Deerfield Management Company, L.p. (series C) made no insider transaction in NeuroMetrix Inc (NURO). Other recent insider transactions involving NeuroMetrix Inc (NURO) include a net sale of 1,000 shares made by Joshua Horowitz ,

In summary, during the past 3 months, insiders sold 0 shares of NeuroMetrix Inc (NURO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 1,000 shares of NeuroMetrix Inc (NURO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 1,000 shares.

NeuroMetrix Inc (NURO)'s detailed insider trading history can be found in Insider Trading Tracker table.

NeuroMetrix Inc Insider Transactions

No Available Data

What does Fibrocell Science Inc do?

Who are the key executives at Fibrocell Science Inc?

Deerfield Management Company, L.p. (series C) is the 10 percent owner & other: Possible Members of 10% Group of Fibrocell Science Inc. Other key executives at Fibrocell Science Inc include 10 percent owner Randal J Kirk , 10 percent owner Intrexon Corp , and director & Chairman and CEO David Pernock .

Fibrocell Science Inc (FCSC) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Fibrocell Science Inc (FCSC) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Fibrocell Science Inc (FCSC) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Fibrocell Science Inc (FCSC)'s detailed insider trading history can be found in Insider Trading Tracker table.

Fibrocell Science Inc Insider Transactions

No Available Data

What does NeurogesX Inc do?

Who are the key executives at NeurogesX Inc?

Deerfield Management Company, L.p. (series C) is the 10 percent owner of NeurogesX Inc. Other key executives at NeurogesX Inc include President and CEO Ron Martell , Exec. V.P. & COO & CFO Stephen F Ghiglieri , and director & 10 percent owner Robert Nelsen .

NeurogesX Inc (NGSX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of NeurogesX Inc (NGSX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of NeurogesX Inc (NGSX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

NeurogesX Inc (NGSX)'s detailed insider trading history can be found in Insider Trading Tracker table.

NeurogesX Inc Insider Transactions

No Available Data

What does Cyclacel Pharmaceuticals Inc do?

Who are the key executives at Cyclacel Pharmaceuticals Inc?

Deerfield Management Company, L.p. (series C) is the 10 percent owner of Cyclacel Pharmaceuticals Inc. Other key executives at Cyclacel Pharmaceuticals Inc include director & President & C.E.O. Spiro Rombotis , director & E.V.P. & Finance & C.O.O. Paul Mcbarron , and Chief Medical Officer Mark Kirschbaum .

Cyclacel Pharmaceuticals Inc (CYCC) Insider Trades Summary

Over the past 18 months, Deerfield Management Company, L.p. (series C) made no insider transaction in Cyclacel Pharmaceuticals Inc (CYCC). Other recent insider transactions involving Cyclacel Pharmaceuticals Inc (CYCC) include a net sale of 194,628,820 shares made by David E. Lazar ,

In summary, during the past 3 months, insiders sold 0 shares of Cyclacel Pharmaceuticals Inc (CYCC) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 12,164,301 shares of Cyclacel Pharmaceuticals Inc (CYCC) were sold and 0 shares were bought by its insiders, resulting in a net sale of 12,164,301 shares.

Cyclacel Pharmaceuticals Inc (CYCC)'s detailed insider trading history can be found in Insider Trading Tracker table.

Cyclacel Pharmaceuticals Inc Insider Transactions

No Available Data

What does Dynavax Technologies Corp do?

Who are the key executives at Dynavax Technologies Corp?

Deerfield Management Company, L.p. (series C) is the 10 percent owner & other: Possible Members of 10% Group of Dynavax Technologies Corp. Other key executives at Dynavax Technologies Corp include Senior Vice President David F Novack , Principal Accounting Officer Justin Burgess , and Chief Medical Officer and VP Robert Janssen .

Dynavax Technologies Corp (DVAX) Insider Trades Summary

Over the past 18 months, Deerfield Management Company, L.p. (series C) made no insider transaction in Dynavax Technologies Corp (DVAX). Other recent insider transactions involving Dynavax Technologies Corp (DVAX) include a net sale of 56,784 shares made by David F Novack , a net sale of 20,526 shares made by Justin Burgess , and a net sale of 3,615 shares made by Francis Cano .

In summary, during the past 3 months, insiders sold 0 shares of Dynavax Technologies Corp (DVAX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 82,425 shares of Dynavax Technologies Corp (DVAX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 82,425 shares.

Dynavax Technologies Corp (DVAX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Dynavax Technologies Corp Insider Transactions

No Available Data

What does VIA Pharmaceuticals Inc do?

Who are the key executives at VIA Pharmaceuticals Inc?

Deerfield Management Company, L.p. (series C) is the 10 percent owner & other: Possible Member of 10% Group of VIA Pharmaceuticals Inc. Other key executives at VIA Pharmaceuticals Inc include 10 percent owner Bay City Capital Llc , 10 percent owner Bay City Capital Fund Iv Co Invesment Fund Lp , and 10 percent owner Bay City Capital Management Iv Llc .

VIA Pharmaceuticals Inc (VIAP) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of VIA Pharmaceuticals Inc (VIAP) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of VIA Pharmaceuticals Inc (VIAP) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

VIA Pharmaceuticals Inc (VIAP)'s detailed insider trading history can be found in Insider Trading Tracker table.

VIA Pharmaceuticals Inc Insider Transactions

No Available Data

What does Arena Pharmaceuticals Inc do?

Who are the key executives at Arena Pharmaceuticals Inc?

Deerfield Management Company, L.p. (series C) is the 10 percent owner of Arena Pharmaceuticals Inc. Other key executives at Arena Pharmaceuticals Inc include director & President and CEO Amit Munshi , EVP & Chief Commercial Officer Robert Lisicki , and Executive VP and CBO Vincent Aurentz .

Arena Pharmaceuticals Inc (ARNA) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Arena Pharmaceuticals Inc (ARNA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Arena Pharmaceuticals Inc (ARNA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Arena Pharmaceuticals Inc (ARNA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Arena Pharmaceuticals Inc Insider Transactions

No Available Data

What does Edgewise Therapeutics Inc do?

Who are the key executives at Edgewise Therapeutics Inc?

Deerfield Management Company, L.p. (series C) is the 10 percent owner & other: Possible Member of 10% Group of Edgewise Therapeutics Inc. Other key executives at Edgewise Therapeutics Inc include CMO Joanne M. Donovan , Chief Financial Officer R Michael Carruthers , and General Counsel John R Moore .

Edgewise Therapeutics Inc (EWTX) Insider Trades Summary

Over the past 18 months, Deerfield Management Company, L.p. (series C) made no insider transaction in Edgewise Therapeutics Inc (EWTX). Other recent insider transactions involving Edgewise Therapeutics Inc (EWTX) include a net sale of 187,542 shares made by Alan J Russell , a net sale of 65,477 shares made by Behrad Derakhshan , and a net sale of 218,563 shares made by R Michael Carruthers .

In summary, during the past 3 months, insiders sold 15,949 shares of Edgewise Therapeutics Inc (EWTX) in total and bought 993,542 shares, with a net purchase of 977,593 shares. During the past 18 months, 664,029 shares of Edgewise Therapeutics Inc (EWTX) were sold and 1,902,632 shares were bought by its insiders, resulting in a net purchase of 1,238,603 shares.

Edgewise Therapeutics Inc (EWTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Edgewise Therapeutics Inc Insider Transactions

No Available Data

What does AdaptHealth Corp do?

Who are the key executives at AdaptHealth Corp?

Deerfield Management Company, L.p. (series C) is the director & 10 percent owner & other: Director by Deputization of AdaptHealth Corp. Other key executives at AdaptHealth Corp include Chief Financial Officer Jason A Clemens , Chief Revenue Officer Shaw Rietkerk , and director & 10 percent owner & other: Director by Deputization James E Flynn .

AdaptHealth Corp (AHCO) Insider Trades Summary

Over the past 18 months, Deerfield Management Company, L.p. (series C) made no insider transaction in AdaptHealth Corp (AHCO). Other recent insider transactions involving AdaptHealth Corp (AHCO) include a net sale of 350,000 shares made by James E Flynn , a net sale of 135,443 shares made by Albert A. Prast , and a net sale of 35,000 shares made by Jason A Clemens .

In summary, during the past 3 months, insiders sold 0 shares of AdaptHealth Corp (AHCO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 560,952 shares of AdaptHealth Corp (AHCO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 560,952 shares.

AdaptHealth Corp (AHCO)'s detailed insider trading history can be found in Insider Trading Tracker table.

AdaptHealth Corp Insider Transactions

No Available Data

What does Werewolf Therapeutics Inc do?

Who are the key executives at Werewolf Therapeutics Inc?

Deerfield Management Company, L.p. (series C) is the 10 percent owner & other: Possible Member of 10% Group of Werewolf Therapeutics Inc. Other key executives at Werewolf Therapeutics Inc include director & 10 percent owner Ra Capital Healthcare Fund Lp , 10 percent owner Mpm Bioventures 2014, L.p. , and 10 percent owner Mpm Oncology Innovations Fund Lp .

Werewolf Therapeutics Inc (HOWL) Insider Trades Summary

Over the past 18 months, Deerfield Management Company, L.p. (series C) made no insider transaction in Werewolf Therapeutics Inc (HOWL). Other recent insider transactions involving Werewolf Therapeutics Inc (HOWL) include a net purchase of 536,426 shares made by Ra Capital Healthcare Fund Lp , a net sale of 4,386 shares made by Mpm Oncology Innovations Fund Lp , and a net sale of 2,425 shares made by Luke Evnin .

In summary, during the past 3 months, insiders sold 0 shares of Werewolf Therapeutics Inc (HOWL) in total and bought 536,426 shares, with a net purchase of 536,426 shares. During the past 18 months, 8,774 shares of Werewolf Therapeutics Inc (HOWL) were sold and 536,426 shares were bought by its insiders, resulting in a net purchase of 527,652 shares.

Werewolf Therapeutics Inc (HOWL)'s detailed insider trading history can be found in Insider Trading Tracker table.

Werewolf Therapeutics Inc Insider Transactions

No Available Data

What does The Oncology Institute Inc do?

Who are the key executives at The Oncology Institute Inc?

Deerfield Management Company, L.p. (series C) is the director & 10 percent owner & other: *Director by Deputization of The Oncology Institute Inc. Other key executives at The Oncology Institute Inc include 10 percent owner M33 Growth I L.p. , director & Chief Executive Officer Brad Hively , and Chief Operating Officer Jeremy Castle .

The Oncology Institute Inc (TOI) Insider Trades Summary

Over the past 18 months, Deerfield Management Company, L.p. (series C) made no insider transaction in The Oncology Institute Inc (TOI). Other recent insider transactions involving The Oncology Institute Inc (TOI) include a net sale of 1,621,801 shares made by Brad Hively , a net sale of 80,000 shares made by Havencrest Healthcare Partners, L.p. , and a net sale of 2,750,000 shares made by M33 Growth I L.p. .

In summary, during the past 3 months, insiders sold 4,726,137 shares of The Oncology Institute Inc (TOI) in total and bought 0 shares, with a net sale of 4,726,137 shares. During the past 18 months, 4,806,137 shares of The Oncology Institute Inc (TOI) were sold and 1,889,378 shares were bought by its insiders, resulting in a net sale of 2,916,759 shares.

The Oncology Institute Inc (TOI)'s detailed insider trading history can be found in Insider Trading Tracker table.

The Oncology Institute Inc Insider Transactions

No Available Data

What does CareMax Inc do?

Who are the key executives at CareMax Inc?

Deerfield Management Company, L.p. (series C) is the director & 10 percent owner & other: *Director by Deputization of CareMax Inc. Other key executives at CareMax Inc include director & 10 percent owner De La Torre Ralph , EVP and COO Solo Alberto De , and director & President and CEO De Solo Carlos A. .

CareMax Inc (CMAXQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of CareMax Inc (CMAXQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of CareMax Inc (CMAXQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

CareMax Inc (CMAXQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

CareMax Inc Insider Transactions

No Available Data

What does Terns Pharmaceuticals Inc do?

Who are the key executives at Terns Pharmaceuticals Inc?

Deerfield Management Company, L.p. (series C) is the 10 percent owner & other: Possible Member of 10% Group of Terns Pharmaceuticals Inc. Other key executives at Terns Pharmaceuticals Inc include Chief Financial Officer Mark J. Vignola , director & 10 percent owner Carl L Gordon , and director & 10 percent owner Orbimed Advisors Llc .

Terns Pharmaceuticals Inc (TERN) Insider Trades Summary

Over the past 18 months, Deerfield Management Company, L.p. (series C) made no insider transaction in Terns Pharmaceuticals Inc (TERN). Other recent insider transactions involving Terns Pharmaceuticals Inc (TERN) include a net sale of 62,000 shares made by Jill M. Quigley , a net purchase of 39,274 shares made by Amy L. Burroughs , and a net sale of 22,397 shares made by Mark J. Vignola .

In summary, during the past 3 months, insiders sold 0 shares of Terns Pharmaceuticals Inc (TERN) in total and bought 48,314 shares, with a net purchase of 48,314 shares. During the past 18 months, 627,612 shares of Terns Pharmaceuticals Inc (TERN) were sold and 552,296 shares were bought by its insiders, resulting in a net sale of 75,316 shares.

Terns Pharmaceuticals Inc (TERN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Terns Pharmaceuticals Inc Insider Transactions

No Available Data

What does Ignyte Acquisition Corp do?

Who are the key executives at Ignyte Acquisition Corp?

Deerfield Management Company, L.p. (series C) is the 10 percent owner & other: Possible Member of 10% Group of Ignyte Acquisition Corp. Other key executives at Ignyte Acquisition Corp include General Counsel Peter David Mccabe , 10 percent owner Sbi Kis 2016-1 Fund , and 10 percent owner 2014 Kif-sbi It Investment Fund .

Ignyte Acquisition Corp (IGNYU) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Ignyte Acquisition Corp (IGNYU) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Ignyte Acquisition Corp (IGNYU) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Ignyte Acquisition Corp (IGNYU)'s detailed insider trading history can be found in Insider Trading Tracker table.

Ignyte Acquisition Corp Insider Transactions

No Available Data

What does PepGen Inc do?

Who are the key executives at PepGen Inc?

Deerfield Management Company, L.p. (series C) is the 10 percent owner & other: *Possible Member of 10% Group of PepGen Inc. Other key executives at PepGen Inc include director & President and CEO James G Mcarthur , Chief Financial Officer Noel Donnelly , and See Remarks Michelle L Mellion .

PepGen Inc (PEPG) Insider Trades Summary

Over the past 18 months, Deerfield Management Company, L.p. (series C) made no insider transaction in PepGen Inc (PEPG). Other recent insider transactions involving PepGen Inc (PEPG) include a net sale of 50,000 shares made by Michelle L Mellion , a net purchase of 51,500 shares made by James G Mcarthur , and a net purchase of 2,557,593 shares made by Ra Capital Healthcare Fund Lp .

In summary, during the past 3 months, insiders sold 0 shares of PepGen Inc (PEPG) in total and bought 59,875 shares, with a net purchase of 59,875 shares. During the past 18 months, 62,959 shares of PepGen Inc (PEPG) were sold and 2,617,468 shares were bought by its insiders, resulting in a net purchase of 2,554,509 shares.

PepGen Inc (PEPG)'s detailed insider trading history can be found in Insider Trading Tracker table.

PepGen Inc Insider Transactions

No Available Data

What does Xilio Therapeutics Inc do?

Who are the key executives at Xilio Therapeutics Inc?

Deerfield Management Company, L.p. (series C) is the 10 percent owner & other: *Possible Member of 10% Group of Xilio Therapeutics Inc. Other key executives at Xilio Therapeutics Inc include director & 10 percent owner & CEO and President Rene Russo , 10 percent owner Atlas Venture Fund Xi, L.p. , and Chief Medical Officer Katarina Luptakova .

Xilio Therapeutics Inc (XLO) Insider Trades Summary

Over the past 18 months, Deerfield Management Company, L.p. (series C) made no insider transaction in Xilio Therapeutics Inc (XLO). Other recent insider transactions involving Xilio Therapeutics Inc (XLO) include a net purchase of 2,245,228 shares made by Gilead Sciences Inc , a net sale of 5,235 shares made by Atlas Venture Fund Xi, L.p. , and a net purchase of 70,000 shares made by James Samuel Shannon .

In summary, during the past 3 months, insiders sold 0 shares of Xilio Therapeutics Inc (XLO) in total and bought 106,289 shares, with a net purchase of 106,289 shares. During the past 18 months, 5,235 shares of Xilio Therapeutics Inc (XLO) were sold and 2,351,517 shares were bought by its insiders, resulting in a net purchase of 2,346,282 shares.

Xilio Therapeutics Inc (XLO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Xilio Therapeutics Inc Insider Transactions

No Available Data

What does Singular Genomics Systems Inc do?

Who are the key executives at Singular Genomics Systems Inc?

Deerfield Management Company, L.p. (series C) is the 10 percent owner & other: *Possible Member of 10% Group of Singular Genomics Systems Inc. Other key executives at Singular Genomics Systems Inc include director & 10 percent owner & Chief Executive Officer Andrew Spaventa , Chief Scientific Officer Eli N. Glezer , and Chief Operating Officer Jyotsna Ghai .

Singular Genomics Systems Inc (OMIC) Insider Trades Summary

Over the past 18 months, Deerfield Management Company, L.p. (series C) made no insider transaction in Singular Genomics Systems Inc (OMIC). Other recent insider transactions involving Singular Genomics Systems Inc (OMIC) include a net sale of 1,850 shares made by Andrew Spaventa , and a net purchase of 122,416 shares made by Kevin C Tang .

In summary, during the past 3 months, insiders sold 0 shares of Singular Genomics Systems Inc (OMIC) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 1,850 shares of Singular Genomics Systems Inc (OMIC) were sold and 122,416 shares were bought by its insiders, resulting in a net purchase of 120,566 shares.

Singular Genomics Systems Inc (OMIC)'s detailed insider trading history can be found in Insider Trading Tracker table.

Singular Genomics Systems Inc Insider Transactions

No Available Data

What does Nuvalent Inc do?

Who are the key executives at Nuvalent Inc?

Deerfield Management Company, L.p. (series C) is the director & 10 percent owner & other: Director by Deputization of Nuvalent Inc. Other key executives at Nuvalent Inc include Chief Financial Officer Alexandra Balcom , See Remarks Darlene Noci , and director & President and CEO James Richard Porter .

Nuvalent Inc (NUVL) Insider Trades Summary

Over the past 18 months, Deerfield Management Company, L.p. (series C) made no insider transaction in Nuvalent Inc (NUVL). Other recent insider transactions involving Nuvalent Inc (NUVL) include a net sale of 324,000 shares made by Matthew Shair , a net sale of 99,016 shares made by Darlene Noci , and a net sale of 72,964 shares made by Deborah Ann Miller .

In summary, during the past 3 months, insiders sold 124,000 shares of Nuvalent Inc (NUVL) in total and bought 0 shares, with a net sale of 124,000 shares. During the past 18 months, 5,067,758 shares of Nuvalent Inc (NUVL) were sold and 0 shares were bought by its insiders, resulting in a net sale of 5,067,758 shares.

Nuvalent Inc (NUVL)'s detailed insider trading history can be found in Insider Trading Tracker table.

Nuvalent Inc Insider Transactions

No Available Data

What does DA32 Life Science Tech Acquisition Corp do?

Who are the key executives at DA32 Life Science Tech Acquisition Corp?

Deerfield Management Company, L.p. (series C) is the director & 10 percent owner & other: Director by deputization of DA32 Life Science Tech Acquisition Corp. Other key executives at DA32 Life Science Tech Acquisition Corp include director & 10 percent owner Keith Crandell , 10 percent owner & other: Director by Deputization Section 32 Fund 3, Lp , and 10 percent owner Arch Venture Fund Xi, L.p. .

DA32 Life Science Tech Acquisition Corp (DALS) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of DA32 Life Science Tech Acquisition Corp (DALS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of DA32 Life Science Tech Acquisition Corp (DALS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

DA32 Life Science Tech Acquisition Corp (DALS)'s detailed insider trading history can be found in Insider Trading Tracker table.

DA32 Life Science Tech Acquisition Corp Insider Transactions

No Available Data

What does Ignyte Acquisition Corp do?

Who are the key executives at Ignyte Acquisition Corp?

Deerfield Management Company, L.p. (series C) is the 10 percent owner & other: Possible Member of 10% Group of Ignyte Acquisition Corp. Other key executives at Ignyte Acquisition Corp include 10 percent owner Ignyte Sponsor Llc , director & 10 percent owner & Co-Chief Executive Officer David I. Rosenberg , and director & 10 percent owner & Co-Chief Executive Officer David J. Strupp .

Ignyte Acquisition Corp (IGNY) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Ignyte Acquisition Corp (IGNY) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Ignyte Acquisition Corp (IGNY) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Ignyte Acquisition Corp (IGNY)'s detailed insider trading history can be found in Insider Trading Tracker table.

Ignyte Acquisition Corp Insider Transactions

No Available Data

What does Mallinckrodt PLC do?

Who are the key executives at Mallinckrodt PLC?

Deerfield Management Company, L.p. (series C) is the 10 percent owner & other: *Possible member of 10% group of Mallinckrodt PLC. Other key executives at Mallinckrodt PLC include 10 percent owner Alta Fundamental Advisers Llc , EVP & Head of Corp Development Jason Daniel Goodson , and director & President and CEO Sigurdur O Olafsson .

Mallinckrodt PLC (MCKPF) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Mallinckrodt PLC (MCKPF) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Mallinckrodt PLC (MCKPF) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Mallinckrodt PLC (MCKPF)'s detailed insider trading history can be found in Insider Trading Tracker table.

Mallinckrodt PLC Insider Transactions

No Available Data

What does Silverback Therapeutics Inc do?

Who are the key executives at Silverback Therapeutics Inc?

Deerfield Management Company, L.p. (series C) is the director & 10 percent owner & other: * Director by deputization of Silverback Therapeutics Inc. Other key executives at Silverback Therapeutics Inc include Chief Operating Officer Brian Dorsey , Chief Legal Officer Alexander A Fitzpatrick , and director & 10 percent owner & other: Director by deputization James E Flynn .

Silverback Therapeutics Inc (SBTX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Silverback Therapeutics Inc (SBTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Silverback Therapeutics Inc (SBTX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Silverback Therapeutics Inc (SBTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Silverback Therapeutics Inc Insider Transactions

No Available Data

What does Peak Bio Inc do?

Who are the key executives at Peak Bio Inc?

Deerfield Management Company, L.p. (series C) is the 10 percent owner & other: Possible Member of 10% Group of Peak Bio Inc. Other key executives at Peak Bio Inc include General Counsel Peter David Mccabe , 10 percent owner Sbi Kis 2016-1 Fund , and 10 percent owner 2014 Kif-sbi It Investment Fund .

Peak Bio Inc (PKBO) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Peak Bio Inc (PKBO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Peak Bio Inc (PKBO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Peak Bio Inc (PKBO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Peak Bio Inc Insider Transactions

No Available Data

What does Frazier Lifesciences Acquisition Corp do?

Who are the key executives at Frazier Lifesciences Acquisition Corp?

Deerfield Management Company, L.p. (series C) is the 10 percent owner & other: Possible Member of 10% Group of Frazier Lifesciences Acquisition Corp. Other key executives at Frazier Lifesciences Acquisition Corp include director & Chief Financial Officer David Joseph Topper , 10 percent owner & other: Possible Member of 10% Group Deerfield Mgmt L.p. , and 10 percent owner & other: Possible Member of 10% Group Deerfield Partners, L.p. .

Frazier Lifesciences Acquisition Corp (FLAC) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Frazier Lifesciences Acquisition Corp (FLAC) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Frazier Lifesciences Acquisition Corp (FLAC) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Frazier Lifesciences Acquisition Corp (FLAC)'s detailed insider trading history can be found in Insider Trading Tracker table.

Frazier Lifesciences Acquisition Corp Insider Transactions

No Available Data

What does ARS Pharmaceuticals Inc do?

Who are the key executives at ARS Pharmaceuticals Inc?

Deerfield Management Company, L.p. (series C) is the director & 10 percent owner & other: * Director by deputization of ARS Pharmaceuticals Inc. Other key executives at ARS Pharmaceuticals Inc include director & 10 percent owner & other: Director by deputization James E Flynn , Chief Commercial Officer Eric Karas , and Chief Legal Officer Alexander A Fitzpatrick .

ARS Pharmaceuticals Inc (SPRY) Insider Trades Summary

Over the past 18 months, Deerfield Management Company, L.p. (series C) made no insider transaction in ARS Pharmaceuticals Inc (SPRY). Other recent insider transactions involving ARS Pharmaceuticals Inc (SPRY) include a net sale of 2,003,260 shares made by Richard E Lowenthal , a net sale of 2,003,260 shares made by Sarina Tanimoto , and a net sale of 529,245 shares made by Justin Chakma .

In summary, during the past 3 months, insiders sold 1,078,120 shares of ARS Pharmaceuticals Inc (SPRY) in total and bought 0 shares, with a net sale of 1,078,120 shares. During the past 18 months, 8,616,909 shares of ARS Pharmaceuticals Inc (SPRY) were sold and 1,401,299 shares were bought by its insiders, resulting in a net sale of 7,215,610 shares.

ARS Pharmaceuticals Inc (SPRY)'s detailed insider trading history can be found in Insider Trading Tracker table.

ARS Pharmaceuticals Inc Insider Transactions

No Available Data

What does Frazier Lifesciences Acquisition Corp do?

Who are the key executives at Frazier Lifesciences Acquisition Corp?

Frazier Lifesciences Acquisition Corp (FLACU) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Frazier Lifesciences Acquisition Corp (FLACU) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Frazier Lifesciences Acquisition Corp (FLACU) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Frazier Lifesciences Acquisition Corp (FLACU)'s detailed insider trading history can be found in Insider Trading Tracker table.

Frazier Lifesciences Acquisition Corp Insider Transactions

No Available Data

What does Korro Bio Inc do?

Who are the key executives at Korro Bio Inc?

Deerfield Management Company, L.p. (series C) is the 10 percent owner & other: Possible Member of 10% Group of Korro Bio Inc. Other key executives at Korro Bio Inc include Chief Financial Officer Vineet Agarwal , 10 percent owner Scott D Sandell , and 10 percent owner New Enterprise Associates 17, L.p. .

Korro Bio Inc (KRRO) Insider Trades Summary

Over the past 18 months, Deerfield Management Company, L.p. (series C) made no insider transaction in Korro Bio Inc (KRRO). Other recent insider transactions involving Korro Bio Inc (KRRO) include a net sale of 11,016 shares made by Vineet Agarwal , a net purchase of 17,857 shares made by Scott D Sandell , and a net purchase of 17,857 shares made by New Enterprise Associates 17, L.p. .

In summary, during the past 3 months, insiders sold 0 shares of Korro Bio Inc (KRRO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 11,016 shares of Korro Bio Inc (KRRO) were sold and 178,570 shares were bought by its insiders, resulting in a net purchase of 167,554 shares.

Korro Bio Inc (KRRO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Korro Bio Inc Insider Transactions

No Available Data

Deerfield Management Company, L.p. (series C) Mailing Address

Above is the net worth, insider trading, and ownership report for Deerfield Management Company, L.p. (series C). Based on the public information released on the U.S. Securities and Exchange Commission (SEC) website, Deerfield Management Company, L.p. (series C)'s mailing address is: New York Ny 10010.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.